Susquehanna International Group, LLP Nrx Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$0.29 - $0.7 $4,582 - $11,060	15,800 Added 88.27%	33,700 $15,000
Q3 2023 Nov 14, 2023	SELL	$0.23 - $0.5 $46 - $100	-200 Reduced 1.1%	17,900 $4,000
Q2 2023 Aug 11, 2023	SELL	$0.46 - $0.89 $46 - $89	-100 Reduced 0.55%	18,100 $8,000
Q1 2023 May 16, 2023	SELL	$0.66 - $1.4 $8,580 - $18,200	-13,000 Reduced 41.67%	18,200 $12,000
Q4 2022 Feb 14, 2023	SELL	$0.79 - $9.19 $27,650 - $321,650	-35,000 Reduced 52.87%	31,200 $34,000
Q3 2022 Nov 14, 2022	BUY	$0.2 - $8.07 $580 - $23,403	2,900 Added 4.58%	66,200 $49,000
Q2 2022 Aug 15, 2022	SELL	$0.51 - $2.42 $33,405 - $158,510	-65,500 Reduced 50.85%	63,300 $38,000
Q1 2022 May 16, 2022	BUY	$2.45 - $5.04 $52,920 - $108,864	21,600 Added 20.15%	128,800 $316,000
Q4 2021 Feb 14, 2022	SELL	$4.5 - $11.91 $142,650 - $377,547	-31,700 Reduced 22.82%	107,200 $512,000
Q3 2021 Nov 15, 2021	BUY	$8.52 - $24.77 $1.18 Million - $3.44 Million	138,900 New	138,900 $1.29 Million

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $81.2M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.